Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Genuity Group Inc., a Vancouver-headquartered, Toronto-listed independent investment dealer. Its research emphasizes growth companies in technology, healthcare, sustainability, consumer and mining, published from Canada, the US, the UK and Australia.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 36312M
- Actions
- 1,56912M
- Ratings / Price targets
- 895 / 674
- Upgrades / Downgrades
- 11 / 22
- Buy-rated
- 82%of 320 rated
- Median upside
- +30.8%
- Targets raised / lowered
- 294 / 248
- On record
- Feb 2012 – Sep 2026
Overview
Canaccord Genuity rated 976 stocks as of February 2026 and describes a coverage universe of more than 1,000 stocks, with an emphasis on growth companies. Its proprietary Quest platform provides valuation data covering about 95% of global market capitalization. The group says it aims for a flat, entrepreneurial organization, with employee shareholders focused on building long-term shareholder value.
The business originated in 1950 as a small regional broker-dealer, renamed Hemsworth, Turton & Co. in 1968. As Canaccord Capital it listed on the Toronto Stock Exchange in 2004 and became Canaccord Financial in 2009. The 2010 purchase of Genuity Capital Markets gave its capital markets arm the Canaccord Genuity name; UK broker Collins Stewart Hawkpoint followed in 2012, and the group adopted its current name in 2013. It sold its US wholesale market-making business to Cantor in November 2025.
Milestones
- 1950
Business originates as a regional broker-dealer
- 1968
Renamed Hemsworth, Turton & Co.
- 2004
Canaccord Capital lists on the Toronto Stock Exchange
- 2010
Acquires Genuity Capital Markets; capital markets rebranded Canaccord Genuity
- 2012
Acquires UK broker Collins Stewart Hawkpoint
- 2013
Renamed Canaccord Genuity Group Inc.
Firm facts
- Legal name
- Canaccord Genuity Group Inc.
- Type
- Full-service
- Founded
- 1950
- Headquarters
- Vancouver, Canada
- Listing
- TSX: CF
- Chairman and Chief Executive Officer
- Dan Daviau
- Rating scale
- BuySpeculative BuyHoldSell12 months
- Website
- canaccordgenuity.com
Research philosophy
We generate actionable ideas from a unique perspective based on in-depth knowledge and a global, independent platform.
Canaccord Genuity pairs its sector analysts with a global strategy team that issues asset-class, sector-allocation and tactical recommendations. Its Quest platform, launched in 1996, is marketed as a way to challenge consensus through consistent, objective cash-flow analysis.
Rating methodology
Since January 2024, Buy has indicated an expected 12-month return above 10%, Hold a return between −10% and 10%, and Sell a return below −10%. A Speculative qualifier identifies higher-risk stocks and can be combined with a rating, as in Speculative Buy.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 Tesla, Inc.TSLA | Buy | $410 |
 Boston Scientific CorporationBSX | Buy | $66 |
 Illumina, Inc.ILMN | Hold | $205 |
 Ulta Beauty, Inc.ULTA | Buy | $731 |
 The Middleby CorporationMIDD | Buy | $160 |
 Strategy IncMSTR | Buy | $179 |
 e.l.f. Beauty, Inc.ELF | Buy | $123 |
 Spire Global, Inc.SPIR | Buy | $22.50 |
 Edwards Lifesciences CorporationEW | Hold | $85 |
 Intuitive Machines, Inc.LUNR | Buy | $39 |
Most active analysts
- William Plovanic40 notesEWBSXAORT
- Maria Ripps37 notesSPOTUPWKLOVE
- Brian McNamara34 notesPLNTSPBLCUT
- Kingsley Crane32 notesBBDDOGCRWD
- Kyle Mikson30 notesVCYTTXGGH
- Joseph Vafi30 notesCORZHUTMSTR
Recent actions
| Date | Stock | Rating action | Rating | Target | Analyst |
|---|---|---|---|---|---|
| Sep 22 | CVCVRx, Inc.CVRX | Target | $10 →$5 | William Plovanic | |
| Sep 22 | YEYETI Holdings, Inc.YETI | Target | $42 →$45 | Brian McNamara | |
| Sep 22 | HTHeartflow, Inc. Common StockHTFL | Target | $45 →$56 | William Plovanic | |
| Sep 22 | PSPasqal Holding S.A. Ordinary SharePSQL | Target | $16 | Kingsley Crane | |
| Sep 18 | SYStryker CorporationSYK | Reiterate | Buy | $400 →$385 | |
| Sep 18 | NANAD | Target | $10 | Susan Anderson | |
| Sep 18 | RAUltragenyx Pharmaceutical Inc.RARE | Target | $37 →$39 | Whitney Ijem | |
| Sep 17 | GNGenerac Holdings Inc.GNRC | Target | $325 →$375 | ||
| Sep 17 |  Fluence Energy, Inc.FLNC | Reiterate | Buy | $24 →$15 | George Gianarikas |
| Sep 17 |  Salesforce, Inc.CRM | Reiterate | Buy |